How to choose the right compound?

Select the right compound according to your experimental needs, e.g., an inhibitor or activator for a specific target, and refer to the IC50 value and activity description of the compound.

What are the stability and storage conditions of these compounds?

All our products have been tested for stability and are accompanied by detailed instructions for storage conditions. Please strictly follow the storage conditions in the instructions to ensure the stability and effectiveness of the products.

Does this compound library contain modulators with specific activity against different PI3K subtypes?

Yes. The PI3K family comprises multiple subtypes that play distinct roles in insulin signaling, inflammation, and cell growth. Our library specifically includes modulators with high subtype selectivity. This is crucial for investigating the unique contributions of specific PI3K subtypes to obesity-related inflammation and insulin resistance.

Inquiry

Products

Online Inquiry

PI3K/Akt/mTOR-Targeted Compounds

Inquiry

PI3K/Akt/mTOR-Targeted Compounds Targets Applications Advantages Publication FAQs

Overview

Fig.1 Overview of PI3K/Akt activation and signalling. Fig.1 PI3K/Akt activation and signalling. (Camaya, et al., 2022)

The PI3K/Akt/mTOR signaling pathway plays a crucial role in the study of obesity and related metabolic diseases. This pathway not only regulates cell growth, proliferation, and metabolism, but is also closely related to the core mechanisms of obesity, such as insulin resistance and fat accumulation. By regulating the PI3K/Akt/mTOR signaling pathway, obesity-related metabolic disorders are effectively ameliorated, providing new strategies and drug targets for obesity management. Protheragen provides a series of PI3K/Akt/mTOR-related compounds for high-throughput screening and mechanism studies in obesity research and related fields.

PI3K/Akt/mTOR-related Products Hold Unlimited Possibilities

Features

Our PI3K/Akt/mTOR-related compound products cover a wide range of inhibitors and activators targeting key nodes of this signaling pathway, including but not limited to PI3K inhibitors, Akt inhibitors, mTOR inhibitors, and compounds capable of modulating molecules upstream and downstream of the pathway. These products undergo stringent quality control and biological activity validation to ensure stability and efficacy in research experiments.

(Source: Bioicons, free)

Activators

(Source: Bioicons, free)

Agonists

(Source: Bioicons, free)

Inhibitors

(Source: Bioicons, free)

Natural Products

Taegets

These compounds offered by our company are suitable for the study of obesity, metabolic disorders, diabetes, and other diseases.

5-alpha Reductase	5-HT receptor	Akt	Annexin A
Anti-infection	Antioxidant	Antiviral	Apoptosis
Aromatase	ATM/ATR	ATPase	Axl
Beta-Amyloid	Calcium channel	cAMP	Cannabinoid receptor
Casein kinase	Chloride channel	cholecystokinin	c-Kit
c-Met	c-Met/HGFR	COX	CRISPR/Cas9
Dehydrogenase	DNA/RNA synthesis	DNA-PK	Dopamine receptor
DPP	DYRK	EGFR	Endothelin receptor
Epigenetic reader domain	ERK	Estrogen receptor/ERR	Ferroptosis
FGFR	FKBP	FLT3	Free radical scavengers
Gamma-secretase	Glucocorticoid receptor	GNRH receptor	GPR
GSK-3	GTPase	Guanylate cyclase	HBV
Hedgehog/Smoothened	HER2	HIV protease	HSP
IGF-1R	IL receptor	Immunology & Inflammation	Influenza virus
IRE1	Kinesin	Leukotriene receptor	Lipoxygenase
MAPK	Melanocortin receptor	Melatonin receptor	MELK
Mitophagy	MMP	MT receptor	mTOR
MyD88	Myosin	NF-κB	Opioid receptor
Oxytocin receptor	P2Y receptor	p38 MAPK	P450
Phosphatase	PAFR	PARP	PDGFR
Pim	Porcupine	Potassium channel	PTEN
ROS	ROS Kinase	SARS-CoV	Serotonin transporter
SGLT	Sigma receptor	STAT	TLR
TNF	Trk receptor	Tyrosinase	VEGFR
Virus protease	Wnt/beta-catenin Nucleoside analog/Antimetabolite

Applications

Metabolic Disorders Research: Our products can be used to regulate lipid metabolism, insulin sensitivity, etc., to study metabolic disorders caused by obesity.
High-Throughput Screening: We provide libraries of compounds for high-throughput screening to rapidly identify potential anti-obesity drugs.
Obesity and Metabolic Research: Our products can be used to explore the mechanism of PI3K/Akt/mTOR signaling pathway in obesity, diabetes, metabolic syndrome, and other diseases.

Advantages of Us

Rich Selection of Compounds

Our lab provides a wide range of compounds covering key targets such as PI3K, Akt, mTOR, etc., which meet different experimental needs and support high-throughput screening and functional studies.

Flexible Specifications & Formats

We offer multiple specifications and dissolution forms to facilitate user selection based on experimental requirements, ensuring efficient and convenient experimental preparation.

Dedicated Research Support

Our experienced research team provides timely, professional troubleshooting and technical consultation services, standing ready to assist clients in resolving issues encountered during their research.

Publication

Title: A novel lnc-RNA, named lnc-ORA, is identified by RNA-Seq analysis, and its knockdown inhibits adipogenesis by regulating the PI3K/AKT/mTOR signaling pathway

Journal: Cells, 2019

DOI: https://doi.org/10.3390/cells8050477

Summary: In this study, we identified lnc-ORA, a novel obesity-associated lncRNA, for the first time and revealed its important role in adipogenesis. By regulating the PI3K/AKT/mTOR signaling pathway, lnc-ORA promotes preadipocyte proliferation and adipocyte differentiation. These findings not only extend our understanding of the regulatory network of lncRNAs in adipogenesis, but also provide new potential targets for the treatment of obesity-related metabolic diseases.

Fig.2 Validation of the differentially expressed lncRNAs by qPCR. Fig.2 Validation of lncRNA differential expression. (Cai, et al., 2019)

Customer Review

Targeted Insulin Signal Resolution
"We utilized Protheragen's PI3K/Akt/mTOR compound library to investigate insulin resistance and compensatory signaling mechanisms. The library's diverse range of specific inhibitors enabled precise resolution of key points within insulin signaling pathways, facilitating subsequent mechanistic studies."— Prof. J* K***

High Selectivity Assurance
"Many molecules in Protheragen's compound library exhibit high selectivity and provide detailed kinase activity data. This ensures we can screen for effective PI3K/Akt/mTOR pathway inhibitors while minimizing non-specific cytotoxicity."— C. D* E***

Frequently Asked Questions

How to choose the right compound?

Select the right compound according to your experimental needs, e.g., an inhibitor or activator for a specific target, and refer to the IC50 value and activity description of the compound.
What are the stability and storage conditions of these compounds?

All our products have been tested for stability and are accompanied by detailed instructions for storage conditions. Please strictly follow the storage conditions in the instructions to ensure the stability and effectiveness of the products.
Does this compound library contain modulators with specific activity against different PI3K subtypes?

Yes. The PI3K family comprises multiple subtypes that play distinct roles in insulin signaling, inflammation, and cell growth. Our library specifically includes modulators with high subtype selectivity. This is crucial for investigating the unique contributions of specific PI3K subtypes to obesity-related inflammation and insulin resistance.

Protheragen is confident that our PI3K/Akt/mTOR-related compounds will be your right hand in obesity research. If you have any questions or need further information, please feel free to contact us. We are committed to providing high-quality compounds and professional technical support to our clients worldwide.

References

Cai, R.; et al. A novel lnc-RNA, named lnc-ORA, is identified by RNA-Seq analysis, and its knockdown inhibits adipogenesis by regulating the PI3K/AKT/mTOR signaling pathway. Cells. 2019, 8(5): 477. (CC BY 4.0)
Camaya, I.; et al. Targeting the PI3K/Akt signaling pathway in pancreatic β-cells to enhance their survival and function: an emerging therapeutic strategy for type 1 diabetes. Journal of Diabetes. 2022, 14(4): 247-260. (CC BY 4.0)

PI3K/Akt/mTOR-Targeted Compounds

PIK-93 (OB0225LY-0088)

CAS No.: 593960-11-3
Pathways: PI3K/Akt/mTOR signaling; Metabolism; Microbiology/Virology; DNA damage/DNA repair
Targets: PIK; PI3K-like kinases (PIKK)
Receptors: ATM; C2β; DNA-PK; hsVps34; mTORC1; p110α; p110β; p110γ; p110δ; PI3K; PI3KIIIβ; PI4K; Virus protease

INQUIRY Datasheet MSDS

BIO-acetoxime (OB0225LY-0090)

CAS No.: 667463-85-6
Pathways: PI3K/Akt/mTOR signaling; Microbiology/Virology; Stem cells; Apoptosis
Targets: GSK-3 family
Receptors: GSK-3α; GSK-3β

INQUIRY Datasheet MSDS

Rapamycin (OB0225LY-0235)

CAS No.: 53123-88-9
Pathways: PI3K/Akt/mTOR signaling; Metabolism; Autophagy; Microbiology/Virology
Targets: PIKK family
Receptors: FKBP; mTOR

INQUIRY Datasheet MSDS

Quercitrin (OB0225LY-0277)

CAS No.: 522-12-3
Pathways: PI3K/Akt/mTOR signaling; Autophagy; Metabolism; Immunology/Inflammation; NF-κB; MAPK
Targets: Reactive oxygen species; S6 Kinase